►

The first criteria for the selection of companies are as follows:

♦ Good expectaion of returns within time periods compatible with the interests of our investors
♦ Led by recognised and reputed scientists who are  committed to the project in the long term
♦ Results that are likely to be patented at the launch of the business

To reach its objectives the previous selection criteria are supplemented with the following, in order to limit the risks of the investment:

► We select the scientific team (team risk)
► We select products that are likely to be validated (technological risk)
► We select products with production costs that can be assumed (development risk)
► Developments that have prices acceptable to the health service (market risk)
► Developments that are of interest to the large pharmaceuticals (market risk)
► Developments that are likely to be approved (regulatory risk)
► Developments that competiors will find difficult to compete with (competition risk)
► Developments with secure patents (competition risk)
► Biotechnology developments at the cutting edge in their early stages, that can meet medical needs that are currently not covered

 
The CRB business model expects returns that multiply the investment severalfold.  To do this CRB invests in products for the mass market, compatible with the priorities of the regulators (FDA/EMEA), with high rate of growth, large margins,  and without the need for additional investments before the concept check.